Shreefal Mehta is an accomplished biotech entrepreneur, scientist, and author who has successfully led several biotech ventures from concept to market. He is the co-founder, Executive Chair, and board member of Pulmokine, a biotech company that is developing a drug for pulmonary hypertension. He is also the founding CEO of PRC Tech LLC, a company that sells high-energy, 2nd-gen lithium-ion supercapacitors for various applications, including backup power in servers and medical devices.

Prior to his entrepreneurial career, Dr. Mehta worked at Cytopia Inc., where he served as VP of Business and Corporate Development, and played a pivotal role in the biotech-pharma alliance between Cytopia and Novartis, which was Australia's largest at the time. He has also led technological commercialization and economic development activities, including the commercial launch of a petrochemical industry analytical X-ray technology that generated millions of annual sales and led to the successful acquisition of the components company.

Dr. Mehta's expertise in biobusiness, pharma, energy storage, and entrepreneurship has earned him invitations to speak at international conferences, including the Indian Science Congress and Australian Biotech Summit. He is also a book author of "Commercializing Successful Biomed Tech," which is recognized as "the bible" and the "roadmap" for bio-entrepreneurs and executives.

Overall, Dr. Mehta's passion for transforming scientific discoveries into successful commercial products has made him a prominent figure in the biotech industry.